SEC Comment Letter 0000000000-24-010883 to REVELATION BIOSCIENCES, INC. (REVB)

REVELATION BIOSCIENCES, INC.
Date: Sept. 25, 2024 · CIK: 0001810560 · Accession: 0000000000-24-010883

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-39603

Date

September 25, 2024

Author

Chester S. Zygmont, III

Form

UPLOAD

Company

REVELATION BIOSCIENCES, INC.

Letter

September 25, 2024 Chester S. Zygmont, III Chief Financial Officer Revelation Biosciences, Inc. 4660 La Jolla Village Drive Suite 100 San Diego, CA 92122 Re:Revelation Biosciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed March 22, 2024 File No. 001-39603 Dear Chester S. Zygmont III: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

September 25, 2024
Chester S. Zygmont, III
Chief Financial Officer
Revelation Biosciences, Inc.
4660 La Jolla Village Drive
Suite 100
San Diego, CA 92122
Re:Revelation Biosciences, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2023
Filed March 22, 2024
File No. 001-39603
Dear Chester S. Zygmont III:
            We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io